免疫检查点抑制剂相关心脏毒性研究进展

Advances in immune checkpoint inhibitor-induced cardiotoxicity

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)是一种新型肿瘤免疫治疗药物,近年来已被广泛应用于多种恶性肿瘤的治疗。但免疫系统的过度激活也会诱发免疫相关不良事件,其中ICIs诱发的心脏毒性包括心肌炎、心包疾病、动脉粥样硬化、血管炎等。ICIs相关心脏毒性虽然发生率不高,但可能导致严重的临床症状,甚至死亡。因此,临床工作中须及时识别和管理ICIs相关心脏毒性,一旦确诊,需根据疾病的严重程度及时进行治疗。ICIs相关心脏毒性的规范化防治需要多学科共同协作,为患者提供全周期个体化监测与管理。

Immune checkpoint inhibitors(ICIs)have emerged as one of the novel immunotherapy drugs in recent years,and been approved for the treatment of multiple tumour types.However,over-activation of the immune system may lead to immune-related advese events,among these,ICIs-induced cardiotoxicity include myocarditis,pericardial disease,atherosclerosis and vasculitis.Although ICIs-induced cardiotoxicity is rare,it may lead to serious clinical complications and even death.Thus,timely identification and management of ICIs-induced cardiotoxicity is vital in clinical practice.Once diagnosed,prompt treatment is required according to the severity of the disease.Standardized prevention and treatment strategies need multidisciplinary collaboration to provide long-term individualized monitoring and management for patients.